Drug intelligence / Profile preview

BCD-178

Development stage: Phase 3
Lead developer: Biocad
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BCD-178 is a biosimilar version of pertuzumab (Perjeta®) being developed by Biocad for the treatment of breast cancer. It is a humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER2 tyrosine kinase receptor. BCD-178 works through two primary mechanisms: as a HER2 antagonist by inhibiting HER2 dimerization and through antibody-dependent cell-mediated cytotoxicity (ADCC). The drug is specifically being developed for HER2-positive breast cancer treatment.

Other names: Pertuzumab biosimilar

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on BCD-178.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCD-178.

Explore the full profile